Xolair 300 MG/2 ML syringe 2ML
Ended Awarded
- Contract number
- SPE2DB26FWEYJ
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $9,302
Award facts
- Contract value 100% obligated
- $9,302.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $9,302.40 to DMS Pharmaceutical Group Inc. for the supply of Xolair (omalizumab) 300 mg/2 mL syringes on a firm fixed-price basis. The delivery order was awarded on November 5, 2025, with an ultimate completion date of November 28, 2025, with performance to take place in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency.
This delivery order represents a continuation of DMS Pharmaceutical Group's critical role as a pharmaceutical supplier to the Department of Defense. The company holds a single-award IDC under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a ceiling value of $499.999 billion and extends through December 31, 2036. The PPV-G GEN V program is part of a broader $30.3 billion acquisition strategy designed to support recurring pharmaceutical and medical supply needs for military healthcare facilities worldwide. DMS Pharmaceutical Group's established track record of delivering diverse therapeutic products—including biologics, specialty pharmaceuticals, and routine medications—demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DB26FWEYJ?
SPE2DB26FWEYJ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 5, 2025.
How much is contract SPE2DB26FWEYJ worth?
The government has obligated $9,302 on SPE2DB26FWEYJ.
Is contract SPE2DB26FWEYJ an order under another contract?
Yes. SPE2DB26FWEYJ is a delivery order under SPE2DB25D9320, an indefinite delivery contract.
Was contract SPE2DB26FWEYJ competed?
The extent of competition for SPE2DB26FWEYJ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award